Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears

Merck CEO Robert Davis has been landing deals “with urgency” over the last few years in an effort to shore up the pipeline ahead of Keytruda’s upcoming patent cliff. But make no mistake: The company ...